Research programme: 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors - vTv Therapeutics

Drug Profile

Research programme: 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors - vTv Therapeutics

Alternative Names: HPP 851

Latest Information Update: 27 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Developer TransTech Pharma; vTv Therapeutics LLC
  • Class Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Metabolic disorders

Most Recent Events

  • 27 Jan 2016 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
  • 21 Sep 2010 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
  • 26 Jan 2008 Preclinical trials in Metabolic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top